TOP RANKING LAW FIRM ROSEN Encourages Lossy Sesen Bio, Inc. Investors to Obtain Lawyer Before Important Oct. 18 Deadline in Securities Class Action – SESN



NEW YORK, September 18, 2021 (GLOBE NEWSWIRE) – WHY: Rosen Law Firm, a global law firm specializing in investor rights, reminds buyers of securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020 and August 17, 2021 inclusive (the “Recourse Period “), the October 18, 2021, lead applicant deadline.

SO WHAT: If you purchased securities of Sesen Bio during the Class Period, you may be entitled to compensation without payment of any costs or direct charges under a contingency fee agreement.

WHAT TO DO NEXT: To join the Sesen Bio class action lawsuit, go to or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action. A class action has already been filed. If you want to serve as the principal applicant, you must move the court no later than October 18, 2021. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies providing reviews do not have comparable experience, resources or peer recognition. Be wise in choosing the right lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company raised more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was appointed by law360 as the Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the defendants throughout the period of the action made false and / or misleading statements and / or failed to disclose that: (1) the clinical trial of Sesen Bio for Vicineum (VB4-845), a locally administered targeted fusion protein (“TFP”) developed as a treatment for Bacillus Calmette-Guérin (“BCG”) – non-muscle invasive bladder cancer (“NMIBC”) unresponsive to the test protocol, including over 2,000 violations were recorded, 215 of which were classified as “major”; (2) three of Sesen Bio’s clinical investigators were found guilty of “serious non-compliance”, including “backdated data”; (3) Sesen Bio had submitted the tainted data as part of the Biologics License Application (“BLA”) for Vicineum; (4) Clinical trials of Sesen Bio have shown that Vicineum infiltrates the body, causing side effects including liver failure and liver toxicity, and increasing the risk of fatal drug-induced liver damage; (5) due to the above, the Company’s BLA for Vicineum was not likely to be approved; (6) due to the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to substantiate the efficacy and safety of Vicineum; and (7) as a result of the foregoing, the defendants’ positive statements about the business, operations and prospects of the Company were substantially misleading and / or lacked reasonable basis. When the real details entered the market, the lawsuit claims that investors have suffered damage.

To join the Sesen Bio class action lawsuit, go to or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action.

No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future recovery does not depend on whether he or she is a lead applicant.

Follow us for updates on LinkedIn:, on Twitter: or on Facebook:

Lawyer advertising. Previous results do not guarantee a similar result.


Contact details:

Laurence Rosen, Esq.
Phillip Kim, Esq.
Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, New York 10016
Phone. : (212) 686-1060
Toll free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]

Main logo



About Author

Leave A Reply